SCHEMBL3963119

SCHEMBL3963119

CCCCCCN(Cc1ccccc1)C(=O)COc1ccc(C[C@H](OCC)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 15/20 0.59
PPARG P37231 12/20 0.59
PPARD Q03181 8/20 0.56
TRPM8 Q7Z2W7 1/20 0.51
CNR2 P34972 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049558 1.00 PPARA (0.59) PPARAPPARGPPARDTRPM8CNR2
SCHEMBL3964391 1.00 PPARA (0.59) PPARAPPARGPPARDTRPM8CNR2
SCHEMBL3962797 0.96 PPARA (0.61) PPARAPPARGPPARDTRPM8
SCHEMBL3960482 0.94 PPARA (0.54) PPARAPPARGPPARD
SCHEMBL3964912 0.93 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL3960794 0.92 TRPM8 (0.52) PPARAPPARGPPARDTRPM8CNR2
SCHEMBL3963033 0.92 PPARA (0.54) PPARAPPARGPPARD
SCHEMBL3960095 0.92 PPARA (0.52) PPARAPPARGPPARD
SCHEMBL3967803 0.92 PPARA (0.56) PPARAPPARGPPARDCNR2
SCHEMBL3960947 0.92 PPARA (0.66) PPARAPPARGPPARDTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514471-B2 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α (PPAR) ASTRAZENECA AB (SE) 2009-04-07 US claimed
EP-1458673-B1 SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) ASTRAZENECA AB (SE) 2006-09-06 EP claimed
US-20050171204-A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) ASTRAZENECA AB (SE) 2005-08-04 US claimed
US-7514471-B2 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α (PPAR) ASTRAZENECA AB (SE) 2009-04-07 US disclosed
US-7488844-B2 Therapeutic agents ASTRAZENECA AB (SE) 2009-02-10 US disclosed
EP-1458673-B1 SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) ASTRAZENECA AB (SE) 2006-09-06 EP disclosed
US-20050282822-A1 Therapeutic agents ASTRAZENECA AB (SE) 2005-12-22 US disclosed
US-20050171204-A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) ASTRAZENECA AB (SE) 2005-08-04 US disclosed
EP-1458673-A1 SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) Astrazeneca AB (SE) 2004-09-22 EP disclosed
WO-2003051821-A1 SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) ASTRAZENECA AB (SE) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282822-A1 Therapeutic agents GPR119, LIPC, PNLIP PPARA 346/4885PPARG 228/4885PPARD 623/4885
US-20050171204-A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) PPARA, PPARD, PPARG PPARA 1/4885PPARG 3/4885PPARD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.